Search

Your search keyword '"Steiss, J. O."' showing total 7 results
Start Over Author "Steiss, J. O." Search Limiters Full Text
7 results on '"Steiss, J. O."'

1. S3 guideline Allergy Prevention

Author

Kopp, M., V, Muche-Borowski, C., Abou-Dakn, M., Ahrens, B., Beyer, K., Blumchen, K., Bubel, P., Chaker, A., Cremer, M., Ensenauer, R., Gerstlauer, M., Gieler, U., Hubner, I. M., Horak, F., Klimek, L., Koletzko, B., V, Koletzko, S., Lau, S., Lob-Corzilius, T., Nemat, K., Peters, E. M. J., Pizzulli, A., Reese, I, Rolinck-Werninghaus, C., Rouw, E., Schaub, B., Schmidt, S., Steiss, J. O., Striegel, A. K., Szepfalusi, Z., Schlembach, D., Spindler, T., Taube, C., Trendelenburg, V, Treudler, R., Umpfenbach, U., Vogelberg, C., Wagenmann, M., Weissenborn, A., Werfel, T., Worm, M., Sitter, H., Hamelmann, E., Kopp, M., V, Muche-Borowski, C., Abou-Dakn, M., Ahrens, B., Beyer, K., Blumchen, K., Bubel, P., Chaker, A., Cremer, M., Ensenauer, R., Gerstlauer, M., Gieler, U., Hubner, I. M., Horak, F., Klimek, L., Koletzko, B., V, Koletzko, S., Lau, S., Lob-Corzilius, T., Nemat, K., Peters, E. M. J., Pizzulli, A., Reese, I, Rolinck-Werninghaus, C., Rouw, E., Schaub, B., Schmidt, S., Steiss, J. O., Striegel, A. K., Szepfalusi, Z., Schlembach, D., Spindler, T., Taube, C., Trendelenburg, V, Treudler, R., Umpfenbach, U., Vogelberg, C., Wagenmann, M., Weissenborn, A., Werfel, T., Worm, M., Sitter, H., and Hamelmann, E.

Abstract

Background: The persistently high prevalence of allergic diseases in Western industrial nations and the limited possibilities of causal therapy make evidence-based recommendations for primary prevention necessary. Methods: The recommendations of the S3 guideline Allergy Prevention, published in its last version in 2014, were revised and consulted on the basis of a current systematic literature search. The evidence search was conducted for the period 06/2013 - 11/2020 in the electronic databases Cochrane and MEDLINE, as well as in the reference lists of current reviews and through references from experts. The literature found was screened in two filtering processes, first by title and abstract, and the remaining papers were screened in the full text for relevance. The studies included after this were sorted by level of evidence, and the study quality was indicated in terms of potential bias (low/high). The revised recommendations were formally agreed and consented upon with the participation of representatives of the relevant professional societies and (self-help) organizations (nominal group process). Of 5,681 hits, 286 studies were included and assessed. Results: Recommendations on maternal nutrition during pregnancy and breastfeeding as well as on infant nutrition in the first months of life again play an important role in the updated guideline: Many of the previous recommendations were confirmed by the current data. It was specified that breastfeeding should be exclusive for the first 4 - 6 months after birth, if possible, and that breastfeeding should continue with the introduction of complementary foods. A new recommendation is that supplementary feeding of cow's milk-based formula should be avoided in the first days of life if the mother wishes to breastfeed. Furthermore, it was determined that the evidence for a clear recommendation for hydrolyzed infant formula in non-breastfed infants at risk is currently no longer sufficient. It is therefore currently reco

Published
2022

2. Abstract of the AWMF-Guideline medical clinical Diagnostics of Mold Fungus Exposure in Indoor Rooms

Author

Wiesmueller, G. A., Heinzow, B., Aurbach, U., Bergmann, K. -C., Bufe, A., Buzina, W., Cornely, O. A., Engelhart, S., Fischer, G., Gabrio, T., Heinz, W., Herr, C. E. W., Kleine-Tebbe, J., Klimek, L., Koeberle, M., Lichtnecker, H., Lob-Corzilius, T., Merget, R., Muelleneisen, N., Nowak, D., Rabe, U., Raulf, M., Seidl, H. P., Steiss, J. -O., Szewzyk, R., Thomas, P., Valtanen, K., Hurrass, J., Wiesmueller, G. A., Heinzow, B., Aurbach, U., Bergmann, K. -C., Bufe, A., Buzina, W., Cornely, O. A., Engelhart, S., Fischer, G., Gabrio, T., Heinz, W., Herr, C. E. W., Kleine-Tebbe, J., Klimek, L., Koeberle, M., Lichtnecker, H., Lob-Corzilius, T., Merget, R., Muelleneisen, N., Nowak, D., Rabe, U., Raulf, M., Seidl, H. P., Steiss, J. -O., Szewzyk, R., Thomas, P., Valtanen, K., and Hurrass, J.

Published
2017

3. Medical Diagnostics for Mold Exposure Indoors

Author

Wiesmueller, G. A., Heinzow, B., Aurbach, U., Bergmann, K. -C., Bufe, A., Buzina, W., Cornely, O. A., Engelhart, S., Fischer, G., Gabrio, T., Heinz, W., Herr, C. E. W., Kleine-Tebbe, J., Klimek, L., Koeberle, M., Lichtnecker, H., Lob-Corzilius, T., Merget, R., Muelleneisen, N., Nowak, D., Rabe, U., Raulf, M., Seidl, H. P., Steiss, J. -O., Szewszyk, R., Thomas, P., Valtanen, K., Hurrass, J., Wiesmueller, G. A., Heinzow, B., Aurbach, U., Bergmann, K. -C., Bufe, A., Buzina, W., Cornely, O. A., Engelhart, S., Fischer, G., Gabrio, T., Heinz, W., Herr, C. E. W., Kleine-Tebbe, J., Klimek, L., Koeberle, M., Lichtnecker, H., Lob-Corzilius, T., Merget, R., Muelleneisen, N., Nowak, D., Rabe, U., Raulf, M., Seidl, H. P., Steiss, J. -O., Szewszyk, R., Thomas, P., Valtanen, K., and Hurrass, J.

Published
2016

4. Poster

Author

Fiebig, H., Weber, B., Cromwell, O., Jutel, M., Fiedler, G., Hanschmann, H., Hansen, I., Stuck, B. A., Hörmann, K., Klimek, L., Jappe, U., Hoffmann, M., Burow, G., Mühlmeier, G., Maier, H., Mušič, E., Košnik, M., Piller, M., Drachenberg, K. J., Urban, E., Schenn, A., Ruëff, F., Weimer, G., Przybilla, B., Sieber, W., Schoppelrey, V., Pfeifer, M., Steiß, J. O., Lindemann, H., Wolf, H., Schnitker, J., Petermann, F., Bergmann, K. C., Zwacka, G., Steinert, B., Markert, U. R., Bijlsma, P. B., Backhaus, B., Weidenhiller, M., Donhauser, N., Hahn, E. G., Raithel, M., Erkelens, W., Hommes, D., Bruno, M., Akkerdaas, J., van Ree, R., Groot, J. A., Taminiau, J. A. J. M., Meinardi, M. M. H. M., Borowski, C., Schäfer, T., Eberhardt, F., Lepp, U., Becker, W.-M., Zabel, P., Hipler, U.-C., Spoo, J., Bauer, A., Elsner, P., Kuefner, M. A., Schwelberger, H. G., Lange, L., Rietschel, E., Riffelmann, F., Lauter, H., Müller, K.-M., Tränkner, A., Mach, K., Reulbach, U., Geyer, D., Leis, B., Ziegert, M., Ahlert, I., Deichmann, K. A., Heinzmann, A., Allmers, H., Beezhold, D., Hamilton, R. G., Sutherland, E. R., Schwanitz, H. J., Scherer, K., Bircher, A. J., Dymek, S., Lex, C., Balzer, S., Schuster, A., Hülsmeier, L., Barker, M., Müller-Lux, A., Göen, T., Koll, W., Koschel, D., Müller-Wening, D., Kütting, B., Janicke, N., Schippke, D., Langer, C., Schulz, T. G., Turowski, S., Drexler, H., Hallier, E., Bickeböller, H., Heutelbeck, A. R. R., Lässig, W., Nordwig, A., Dellweg, D., Schwarz, H., Goldmann, R., Lorenz, C., Achtzehn, U., Stehle, R., Keiper, B., Jilge, B., Beier, L., Schmidt, E. W., van Kampen, V., Haamann, F., Merget, R., Sander, I., Raulf-Heimsoth, M., Rabstein, S., Brüning, T., Ahrens, T., Muesken, H., Bergmann, K.-Ch., Vetter, M., Heitmann, M., Hunzelmann, N., Schuster, J., Kadar, J., Kespohl, S., Petersen, A., Meyer, H. E., Sickmann, A., Kleber, N., Hinrichs, J., Schocker, F., Becker, W. M., Rozynek, P., Dresselhaus, T., Reuter, B., Henzgen, M., Fahlbusch, B., Rudeschko, O., Schlenvoigt, G., Kroegel, C., Rihs, H.-P., Gaspar, Â., Pires, G., Hohenstein, E., Fiedler, E.-M., v. Pelchrzim, R., Focke, M., Zuberbier, T., Worm, M., Janowska, E., Grycmacher-Łapko, V., Kurek, M., Lippert, U., Niedenführ, S., Fuchs, T., Ludwig, A., Koch, A., Balda, B.-R., Oestmann, E., Philipp, S., Spornraft-Ragaller, P., Hammermann, J., Meurer, M., Ott, H., Wurpts, G., Krieg, R., Al Masaoudi, T., Joussen, S., Kiehl, K., Neis, M., Merk, H. F., Baron, J. M., Schmengler, J., John, S. M., Blaschke, V., Bonnekoh, B., Holzamer, N., Schmidt, U., Ambach, A., Oppermann, H., Thriene, B., Gollnick, H., Kraus, T., Häberle, M., Hoopmann, M., Hehl, O., Werfel, T., Heidrich, S., Kelber, J., Hünecke, P., Kasche, A., Klaus, S., Thiel, M., Buters, J., Weichenmeier, I., Ring, J., Traidl-Hoffmann, C., Behrendt, H., Krämer, U., Lau, S., Kim, S., Mahling, H., Schulz, G., Keil, T., Wahn, U., Mock, B., Kugler, J., Cremer, R., Sandner, B., Kaiser, F., Herbst, R. A., Wahl, R., Suck, R., Kügler, K., Frosch, P. J., Nabe, A., Konturek, P., Simon, K., Kressel, J., Nägel, A., Wilken, V., Strehfeld, T., Neubert, K., Pieper, B., Kuhn, M., Winterkamp, S., Pacurar, A., Senger, D., Beskitas, E., Dorrmann, H., Mueller, M. W., Harwanegg, C., Hiller, R., Kinne, R. W., Schröder, C. M., Mahler, V., Schröder, A., Erdmann, S., Schultis, H. W., Buchwald, F., Hampel, W., Maiss, J., Naegel, A., Zahradnik, E., Doekes, G., Runge, D. M., Schwertner, H., Grize, L., Schindler, C., Surber, Ch., Böckelmann, R., Horn, T., Breithaupt, S., Thiele, J. J., Gutermuth, J., Jakob, T., Heinzelmann, J., Varosi, F., Debevc, F., Pöhlmann, T. G., Seyfarth, L., Kindt, F., Löser, C., Niemeier, V., Gieler, U., Kummer, W., Haberberger, R. V., Klockenbring, T., Stöcker, M., Huhn, M., Bauer, R., Goerlich, R., Fischer, R., Barth, S., Suchodolska, A., Soost, S., Bayerl, C., Ludwig, B., Gancs, P., Häusermann, P., Harr, T., Müller, M., Sachs, B., Riegel, S., Schichler, D., Schrooten, J., Heussen, N., Hilgers, R.-D., Seo, J. W., Franke, I., and Strauss, R.

Subjects
SIT und Insektengiftallergie, Immunology and Allergy
Published
2004

5. WDR73 Mutations Cause Infantile Neurodegeneration and Variable Glomerular Kidney Disease

Author

Vodopiutz, J. (Julia), Seidl, R. (Rainer), Prayer, D. (Daniela), Khan, M.I. (M. Imran), Mayr, J.A. (Johannes A.), Streubel, B. (Berthold), Steiß, J.-O. (Jens-Oliver), Hahn, A. (Andreas), Csaicsich, D. (Dagmar), Castro, C. (Christel), Assoum, M. (Mirna), Müller, T. (Thomas), Wieczorek, D. (Dagmar), Mancini, G.M.S. (Grazia), Sadowski, C.E. (Carolin E.), Lévy, N. (Nicolas), Megarbane, A. (Andre), Godbole, K. (Koumudi), Schanze, D. (Denny), Hildebrandt, F. (Friedhelm), Delague, V. (Valérie), Janecke, A.R. (Andreas), Zenker, M. (Martin), Vodopiutz, J. (Julia), Seidl, R. (Rainer), Prayer, D. (Daniela), Khan, M.I. (M. Imran), Mayr, J.A. (Johannes A.), Streubel, B. (Berthold), Steiß, J.-O. (Jens-Oliver), Hahn, A. (Andreas), Csaicsich, D. (Dagmar), Castro, C. (Christel), Assoum, M. (Mirna), Müller, T. (Thomas), Wieczorek, D. (Dagmar), Mancini, G.M.S. (Grazia), Sadowski, C.E. (Carolin E.), Lévy, N. (Nicolas), Megarbane, A. (Andre), Godbole, K. (Koumudi), Schanze, D. (Denny), Hildebrandt, F. (Friedhelm), Delague, V. (Valérie), Janecke, A.R. (Andreas), and Zenker, M. (Martin)

Abstract

Infantile-onset cerebellar atrophy (CA) is a clinically and genetically heterogeneous trait. Galloway-Mowat syndrome (GMS) is a rare autosomal recessive disease, characterized by microcephaly with brain anomalies including CA in some cases, intellectual disability, and early-infantile-onset nephrotic syndrome. Very recently, WDR73 deficiency was identified as the cause of GMS in five individuals. To evaluate the role of WDR73 mutations as a cause of GMS and other forms of syndromic CA, we performed Sanger or exome sequencing in 51 unrelated patients with CA and variable brain anomalies and in 40 unrelated patients with a diagnosis of GMS. We identified 10 patients from three CA and from two GMS families with WDR73 mutations including the original family described with CA, mental retardation, optic atrophy, and skin abnormalities (CAMOS). There were five novel mutations, of which two were truncating and three were missense mutations affecting highly conserved residues. Individuals carrying homozygous WDR73 mutations mainly presented with a pattern of neurological and neuroimaging findings as well as intellectual disability, while kidney involvement was variable. We document postnatal onset of CA, a retinopathy, basal ganglia degeneration, and short stature as novel features of WDR73-related disease, and define WDR73-related disease as a new entity of infantile neurodegeneration.

Published
2015
Full Text
View/download PDF

7. Monitoring of omalizumab therapy in children and adolescents.

Author

Steiß JO, Schmidt A, Lindemann H, Rudloff S, Staatz A, Strohner P, Becher G, Nährlich L, and Zimmer KP

Abstract

Background: Omalizumab is a successfully implemented supplementary therapy for improving asthma control in children aged 6 years and older with severe persistent allergic asthma. The dosage of omalizumab depends on body weight and IgE level, yet no parameter has been established to guide dosage changes during therapy. Clinical studies in patients with allergic asthma or allergic rhinitis revealed a clinically relevant improvement by using omalizumab leading to concentrations of free serum IgE reported to be lower than 50 ng/ml. Therefore, only the question concerning the concentrations of free IgE used in a therapy with omalizumab is regarded of clinical importance, while total IgE (free and omalizumab-bound IgE) increases during treatment., Patients and Methods: Ten patients, 8 to 17 years of age, received therapy with omalizumab due to severe allergic asthma. In addition, the patients had pronounced rhinoconjunctivitis, food allergy, insect sting allergy, and/or neurodermitis. The total IgE in the serum was measured in the patients 3 - 6 months before each omalizumab injection as a potential progress parameter (Sandwich-Immunoassay ADVIA Centaur)., Results: Six months after beginning of the therapy with omalizumab, a significant decrease of the total IgE concentration was found, in comparison to the baseline values (p < 0.003). In all patients the tolerability of omalizumab was very good: there was a reduction in the frequency of the asthma exacerbations and rescue medications. All patients reported a clearly improved quality of life., Conclusions: A general increase in IgE was not observed in any of the children we treated with omalizumab. Apart from the development of routine assays to determine free serum IgE levels, the significance of the total serum IgE as a suitable control of an omalizumab therapy should be further investigated in controlled studies with regard to sensitivity and specificity. In order to only administer the lowest necessary dose of omalizumab especially in children and adolescents, the establishment of laboratory parameters (free IgE and/or total IgE) to adequately monitor the therapy is urgently needed. Patients undergoing an omalizumab therapy require medical supervision at close intervals., (© Dustri-Verlag Dr. K. Feistle.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results